Cardiac transplantation: the final therapeutic option for the treatment of heart failure

被引：15

作者：

Koerner, MM ^{[1
]}

Durand, JB ^{[1
]}

Lafuente, JA ^{[1
]}

Noon, GP ^{[1
]}

Torre-Amione, G ^{[1
]}

机构：

[1] Baylor Coll Med, Houston, TX 77030 USA

来源：

CURRENT OPINION IN CARDIOLOGY | 2000年 / 15卷 / 03期

关键词：

D O I：

10.1097/00001573-200005000-00010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

End-stage heart failure is still associated with a decrease in quality and prognosis of life. Cardiac transplantation remains the final extraordinary therapeutic option for the treatment of truly irreversible end-stage heart failure in all age groups. The selection process of candidates and the acceptance of patients with relative contra-indications is characterized by the experience and skills of an interdisciplinary transplant team, which should have access to different mechanical circulatory support systems for short-term or long-term use: bridging to transplant as well as for recovery. (C) 2000 Lippincott Williams & Wilkins, Inc.

引用

收藏

页码：178 / 182

页数：5

相关论文

共 37 条

[1] Mortality remains high for outpatient transplant candidates with prolonged (>6 months) waiting list time [J].

Aaronson, KD ;

Mancini, DM .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (05) :1189-1195

[2] Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure [J].

Auricchio, A ;

Stellbrink, C ;

Block, M ;

Sack, S ;

Vogt, J ;

Bakker, P ;

Klein, H ;

Kramer, A ;

Ding, J ;

Salo, R ;

Tockman, B ;

Pochet, T ;

Spinelli, J .

CIRCULATION, 1999, 99 (23) :2993-3001

[3]

Bartling B, 1999, CIRCULATION, V100, P216

[4] Heart transplantation in patients 70 years of age and older: Initial experience [J].

Blanche, C ;

Matloff, JM ;

Denton, TA ;

Czer, LSC ;

Fishbein, MC ;

Takkenberg, JJM ;

Trento, A .

ANNALS OF THORACIC SURGERY, 1996, 62 (06) :1731-1736

[5] An analysis of the effect of age on survival after heart transplant [J].

Borkon, AM ;

Muehlebach, GF ;

Jones, PG ;

Bresnahan, DR ;

Genton, RE ;

Gorton, ME ;

Long, ND ;

Magalski, A ;

Porter, CB ;

Reed, WA ;

Rowe, SK .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1999, 18 (07) :668-674

[6] DOSE-RESPONSE OF CHRONIC BETA-BLOCKER TREATMENT IN HEART-FAILURE FROM EITHER IDIOPATHIC DILATED OR ISCHEMIC CARDIOMYOPATHY [J].

BRISTOW, MR ;

OCONNELL, JB ;

GILBERT, EM ;

FRENCH, WJ ;

LEATHERMAN, G ;

KANTROWITZ, NE ;

ORIE, J ;

SMUCKER, ML ;

MARSHALL, G ;

KELLY, P ;

DEITCHMAN, D ;

ANDERSON, JL .

CIRCULATION, 1994, 89 (04) :1632-1642

[7]

COSTANZO MR, SELECTION TREATMENT

[8] Safety and efficacy of a soluble P75 tumor necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure [J].

Deswal, A ;

Bozkurt, B ;

Seta, Y ;

Parilti-Eiswirth, S ;

Hayes, FA ;

Blosch, C ;

Mann, DL .

CIRCULATION, 1999, 99 (25) :3224-3226

[9] TNF-α and heart failure -: The difference between proof of principle and hypothesis testing [J].

Francis, GS .

CIRCULATION, 1999, 99 (25) :3213-3214

[10] Tumor necrosis factor-α -: A mediator of disease progression in the failing human heart [J].

Herrera-Garza, EH ;

Stetson, SJ ;

Cubillos-Garzon, A ;

Vooletich, MT ;

Farmer, JA ;

Torre-Amione, G .

CHEST, 1999, 115 (04) :1170-1174

← 1 2 3 4 →